Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum subsp. infantis
- Development stage
- Phase 4
- Lead developer
- Emanual Maverakis, MD
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bifidobacterium longum subsp. infantis* (*B. infantis*) is a Gram-positive, anaerobic bacterium and a specialized subspecies of the *Bifidobacterium longum* species, primarily known for its role as a key commensal in the infant gut microbiome. It is uniquely adapted to utilize human milk oligosaccharides (HMOs) found in breast milk, which it ferments into short-chain fatty acids (SCFAs) like acetate and lactate. This metabolic activity acidifies the intestinal environment, inhibiting the growth of pathogens and promoting gut barrier integrity. In clinical research led by Emanual Maverakis, MD, at the University of California, Davis, *B. infantis* is being evaluated as a probiotic dietary supplement for healthy breastfed newborns. The Phase I study (NCT04750473) investigates the safety and optimal dosing required for stable gut colonization, with the long-term goal of preventing immune-mediated conditions such as atopic dermatitis (eczema) and food allergies by fostering early-life immune tolerance.
- Brand names
- Evivo
- Other names
- B. infantisBifidobacterium infantis
Beyond the preview
Go deeper on Bifidobacterium longum subsp. infantis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum subsp. infantis.